Zohra Nooruddin
Overview
Explore the profile of Zohra Nooruddin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frei C, Ryan K, Obodozie-Ofoegbu G, Moore A, Teng C, Lucero K, et al.
Leuk Lymphoma
. 2024 Jun;
65(10):1520-1523.
PMID: 38832701
No abstract available.
2.
Ta A, Kaur S, Mader M, Franklin K, Williams M, Williams R, et al.
Leuk Lymphoma
. 2024 Apr;
65(8):1090-1099.
PMID: 38619488
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly...
3.
Mines I, Al-Abayechi A, Kaur S, Nooruddin Z
Cureus
. 2024 Apr;
16(3):e55399.
PMID: 38562334
Hyperviscosity is an uncommon manifestation of various underlying diseases. Rapid diagnosis and management of the underlying disease is crucial to prevent significant complications, including hypertension, cerebral vascular accidents, pulmonary embolism,...
4.
Alkadimi M, Aldawoodi T, Lucero K, Fierro M, Boyle L, Mader M, et al.
Oncologist
. 2024 Jan;
29(5):369-376.
PMID: 38254242
Purpose: This study retrospectively reviewed the outcomes of patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab with bevacizumab (A + B) therapy at the Veterans Health Administration (VHA). Patients And...
5.
Roman Souza G, Nooruddin Z, Lee S, Boyle L, Lucero K, Ananth S, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Dec;
24(3):e67-e77.
PMID: 38151390
Introduction: Our retrospective study evaluates the impact of time from diagnosis to treatment (TDT) on outcomes of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated within the Veterans...
6.
Moore A, Nooruddin Z, Reveles K, Datta P, Whitehead J, Franklin K, et al.
Curr Oncol
. 2023 Sep;
30(9):8411-8423.
PMID: 37754526
Background: Durvalumab is approved for the treatment of adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This real-world study describes patient characteristics and durvalumab treatment patterns...
7.
Moore A, Nooruddin Z, Reveles K, Koeller J, Whitehead J, Franklin K, et al.
Oncologist
. 2023 Jun;
28(9):804-811.
PMID: 37335901
Background: Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for use in adults with unresectable stage III non-small cell lung cancer (NSCLC)...
8.
Walker C, Horowitz A, Nooruddin Z, Frei C
J Oncol Pharm Pract
. 2023 Jun;
30(4):673-677.
PMID: 37309168
Purpose: Ibrutinib is a tyrosine kinase inhibitor that is increasingly prescribed in chronic lymphocytic leukemia (CLL). Invasive fungal infections (IFIs) have been reported early after ibrutinib initiation. Timing of IFIs...
9.
Lucero K, Obodozie-Ofoegbu O, Nooruddin Z, Ryan K, Castillo A, Moore A, et al.
J Manag Care Spec Pharm
. 2023 Mar;
29(4):420-430.
PMID: 36989449
Novel agents (NAs) (ibrutinib, idelalisib, and venetoclax) were first introduced in 2013 as therapeutic options to treat chronic lymphocytic leukemia (CLL). To determine if the uptake of NAs for first-line...
10.
Frei C, Le H, McHugh D, Ryan K, Jones X, Galley S, et al.
Leuk Lymphoma
. 2021 Feb;
62(7):1664-1673.
PMID: 33569992
The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205...